Humacyte (HUMA) Capital Expenditures (2020 - 2026)

Humacyte (HUMA) has reported Capital Expenditures for 7 consecutive years, with $104000.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Capital Expenditures fell 58.57% year-over-year to $104000.0 in Q2 2026; TTM through Jun 2026 was $367000.0, a 79.53% decrease from a year earlier, with the FY2025 full-year figure at $884000.0, down 43.77% from the prior year.
• Capital Expenditures was $104000.0 for Q2 2026 at Humacyte, down from $175000.0 in the prior quarter.
• Over five years, Capital Expenditures peaked at $1.2 million in Q1 2023 and troughed at $30000.0 in Q1 2022.
• A 5-year average of $336833.3 and a median of $197500.0 in 2022 frame the typical range for Capital Expenditures.
• Across the five-year window, Capital Expenditures soared 3740.0% in 2023 and slumped 94.75% in 2025, its largest moves.
• Over 5 years, Capital Expenditures stood at $681000.0 in 2022, then sank by 77.97% to $150000.0 in 2023, then sank by 58.0% to $63000.0 in 2024, then tumbled by 38.1% to $39000.0 in 2025, then soared by 166.67% to $104000.0 in 2026.
• The last three Capital Expenditures figures came in at $104000.0 (Q2 2026), $175000.0 (Q1 2026), and $39000.0 (Q4 2025), per Business Quant data.